IPO GMP Live Updates: Aditya Infotech subscribed 50% on day 1; NSDL, Shanti Gold lead the GMP race
Key IPOs This Week
NSDL
Aditya Infotech
Laxmi India Finance
Sri Lotus Developers
Shanti Gold
NSDL IPOIndia's largest depository is set to launch its IPO on July 30, targeting ₹4,012 crore through an offer for sale. The price band is fixed at ₹760–₹800 per share, with ICICI Securities serving as the lead manager.
Aditya Infotech IPO
Backed by ICICI Securities, this ₹1,300 crore mainboard IPO opens on July 29 and closes on July 31. The IT services company has set the price band at ₹640–₹675 per share.
Retail Investors: 10%
Non-Institutional Investors (NII): 15%
Qualified Institutional Buyers (QIBs): 75%
Discounted allocation for employees (~₹6 crore reserve, ₹60/share discount) NSDL
Aditya Infotech
Laxmi India Finance
Sri Lotus Developers
Shanti Gold Subscription Window: Opens July 29, 2025 and closes July 31, 2025.
Allotment Date: 01 Aug, 2025
Listing Date: 05 Aug, 2025 Price Band: ₹640–₹675 per share; minimum application is 22 shares (₹14,080). IPO Size: ₹1,300 crore total
Rs 500 crore via fresh equity issue
Rs 800 crore via Offer for Sale (OFS) by promoters The issue's grey market premium trades at Rs 240-250. Total: 0.47 times Employee Reserved: 0.39 timesRetail Individual Investors (RIIs): 1.73 times Non Institutional Investors(NIIS): 0.56 times Qualified Institutional Buyers (QIBs): 0.00 times
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India.com
25 minutes ago
- India.com
Masterstroke by Mukesh Ambani as Reliance to invest Rs 4300000000 in Bengaluru-based startup, it deals in..., name is...
Mukesh Ambani (File) In a significant decision which could provide a major boost to India's growing spacetech industry, Mukesh Ambani-led Reliance Industries is mulling to invest $50 million (about Rs 430 crore) in Digantara Research & Technologies, a Bengaluru-based spacetech startup, which is developing technology that can track objects in the Earth's orbit. How much is Mukesh Ambani Reliance Industries investing? According to a report by The Economic Times, Reliance Industries, India's most valued domestic firm led by billionaire Mukesh Ambani, is in advanced discussions to lead a Rs 430 crore funding round in Digantara, along with existing investors like Peak XV Partners. 'Reliance has evaluated multiple startups in the spacetech segment. It is looking at companies building novel solutions in the sector. Its talks with Digantara are at an advanced stage,' the report quoted a source familiar with the matter as saying. What does Digintara do? Co-founded by Anirudh Sharma (CEO), Rahul Rawat (COO), and Tanveer Ahmed (CTO), Digintara is a spacetech startup based in Bengaluru, working on the development of technologies which can track bjects in Earth's orbit. Earlier, in March, Digintara launched a satellite capable of tracking debris as small as 5 cm, and is currently providing services to defence agencies in both India and the United States, as per the report. According to the report, Digintara plans to deploy a constellation of about a dozen surveillance satellites by the end of 2026. The company has launched three satellites so far, one of which is part of the proposed satellite constellation. A major chunk of the upcoming funding round will be dedicated in developing and launching these satellites. 'Given the volatility in global geopolitics, every country is focused on having its own indigenous sovereign solutions that can be controlled in times of crisis. That's where the opportunity lies for startups like Digantara,' the report quoted a source as saying. The company established a manufacturing and operations facility in the US in February 2024, and expects to earn a revenue of $25–30 million (Rs 220–260 crore) from its US operation in the next 2-3 years.
NDTV
39 minutes ago
- NDTV
Hot Dogs, Selfies, Sneakers: Humanoid Robot Grabs New York City's Attention
New Delhi: A humanoid robot marched through Midtown Manhattan last week, causing a stir and drawing shocked stares in the heart of New York City. The robot, branded KOID and priced at around $100,000 (Rs 87.2 lakh), was deployed by global asset management firm KraneShares in a marketing stunt to promote its new Global Humanoid and Embodied Intelligence Index ETF, which launched in June. The robot had previously rung the Nasdaq opening bell. During the stunt, KOID was seen walking along Fifth Avenue, grabbing a hot dog, posing for selfies, and even walking into a Hoka store, where startled staff helped it try on sneakers. The event was filmed and posted to Instagram. View this post on Instagram A post shared by New Yorkers (@newyorkers) A blind man praised the technology as "wonderful," suggesting it could one day help people who can't use guide dogs due to allergies or other issues. Another passerby said, "I mean, I would love for it to clean my house." Not all reactions were positive. "To mess with humanity . . . y'all gotta stop. Satan, I rebuke you to hell," one man yelled. Asked about a potential robot-led future, a woman said, "It's going to happen." The robot was built by Chinese robotics company Unitree and supplied by Long Island-based RoboStore. It operates using Stanford's OpenMind software and, while remote-controlled during the Midtown walk, is fully programmable and already in use at research labs and universities. Since the ETF's launch, KraneShares reports $28 million in assets under management. According to KraneShares' marketing head Joseph Dube, "At some point these robots will be so common that it's not going to have the wow factor that it currently has. We're definitely taking advantage of a moment in time." According to the Morgan Stanley Global Humanoid Model, the humanoid robotics market could grow to 1 billion units and generate $5 trillion in annual revenue by 2050.
India Today
41 minutes ago
- India Today
How Trump tariffs could impact Indian pharma's $8.7 bn dream run
For long, the high-value US market has driven the growth of the storied Indian generic drugs industry, where companies like Cipla, Sun Pharma and Dr Reddy's Laboratories, among others, have successfully challenged hundreds of off-patent drugs in the US and established a soaring business FY24, India exported $8.7 billion (Rs 76,113 crore) worth of pharma products to the US, which comprises over 11 per cent of India's total merchandise exports to that the same period, India exported $77.5 billion (Rs 6.8 lakh crore) worth of merchandise goods to the US and imported $42.2 billion (Rs 3.7 lakh crore) worth of goods from it, resulting in a trade surplus of $35.3 billion (Rs 3 lakh crore) in India's US is India's largest destination for pharma exports, accounting for over 31 per cent of the country's total pharmaceutical exports. As much as 47 per cent of all generics consumed in the US are imported from India. However, the Donald Trump administration's threat of imposition of a 25 per cent reciprocal tariff from August 1 (up from 0 to 6.7 per cent at present) has thrown the Indian pharma industry in a bind. Shares of Indian pharma companies, led by Sun Pharma, fell close to 6 per cent on the NSE (National Stock Exchange) on August 1 following president Trump's statements on the tariff imposition, and his letters to 17 top US pharma companies asking them to reduce their rates in line with what prevailed in other countries. Some fear Trump may send a similar letter to Sun Pharma, which earns as much as 20 per cent of its total revenues from the US Indian industry was hoping against hope that Trump would not hike tariffs on generic drugs since these are life-saving. However, Trump had indicated earlier this year too that tariffs on pharma products would be 25 per cent from April 2 onwards, without pinpointing any nation. He later gave a 90-day reprieve to countries, and the new deadline for the tariffs was put as August imports roughly $800 million worth of pharmaceutical products from the US, and imposes a tariff of 10 per cent. Experts say that even if higher tariffs are imposed on active pharma ingredients (APIs), which are raw materials going into pharma production, India could still be competitive, if tariffs on other API-supplying countries are higher than that of the US will still be dependent on countries like India since the cost of manufacturing certain drugs in the US would be at least six times compared to that of manufacturing the same product in India, say industry US market, which relies heavily on India for APIs and low-cost generics, would struggle to find alternatives, according to Namit Joshi, chairman of Pharmexcil (Pharmaceuticals Export Promotion Council of India). 'Efforts to shift pharmaceutical manufacturing and API production to other countries or within the US will take at least 3-5 years to establish meaningful capacity,' he was quoted in media reports. advertisement'There is no need for panic. The industry should lie low for now since the US has not yet increased the tariffs. Who else can give the US such competitively-priced goods in large quantities and high quality?' Daara Patel, secretary general of the Indian Drug Manufacturers Association, had said in an interview to INDIA TODAY in April. 'Even if it increases up to 10 per cent, the industry should be able to absorb it or pass it on to the US consumers. They would not mind paying for it since it all works on insurance money,' he what if the US decides to go for a higher tariff? 'In case the US raises tariffs beyond 15 per cent, India will have to look at newer markets in East Africa and the Middle East. These markets are neither high value nor high in volumes, but it will be a better option than dealing with an uncertain US market alone,' Patel had saidSubscribe to India Today Magazine- EndsTune InMust Watch
